Our proprietary platform technology is designed to inhibit cancer cell proliferation by stimulating a natural antibody response against targeted growth factors.
We design synthetic therapeutics that include immunogenic sequence of growth factors domain that are expressed with a synthetic carrier.
Growth factors are natural occurring proteins that are recognized by the body that will not normally be targeted by the body’s immune system. We have developed a proprietary platform that can create synthetic molecules that stimulate an antibody response targeting specific growth factors proteins active in tumour proliferation.
Our innovative approach allows us to develop novel mono- or bi-specific therapeutics, in order to treat cancers which are often controlled by multiple growth factor-triggered pathways.
Single targeted synthetic molecule
Multi targeted synthetic molecule